高血压患者静息心率与β-受体阻滞剂使用现况调查

目的调查我国高血压患者静息心率受体阻滞剂使用率及静息心率达标情况,为临床决策提供依据方法采用横断面调查的方法收集2014年6月~2015年6月我国18个城市,20家二级以上医院连续就诊的高血压患者8767例,测量其血压和静息心率,记录降压药物使用情况结果高血压患者平均静息心率为(75.1±11.7)次/分,受体阻滞剂使用率为11.3% 73.3%的高血压患者静息心率达标(W80次/分);23, 6%的患者静息心率未达标,也未使用p-受体阻滞剂;3.0%的患者使用B-受体阻滞剂后静息心率仍未达标中青年组和老年组高血压患者B-受体阻滞剂使用率比较差异无统计学意义(H.7%比10.9%/>0.05),但老年组患者静息心率低于中青年组[(73.7±11.3)次/分比(76.2±11.9)次/分],静息心率达标率高于中青年组(77.9%比72.0%),差异均有统计学意义(P<0.05)结论我国高血压患者静息心率达标率偏低.可能与B-受体阻滞剂使用率低有关。

Status survey on resting heart rate and usage of p-receptor blockers in patients with hypertension

Objective To investigate the status of restiong heart rate, usage rate of β-receptor blockers and achieved resting heart rate controlling in patients with hypertension in our countiy, which provided evidence for making clinical decision.Methods A total of 8 767 patients with hypertension were consecutively recruited from June 2014 to June 2015 in 20 secondary or tertiary hospitals of 18 cities in China by cross-sectional study.Blood pressure and resting heart rate were measured and uses of antihypertensive drugs were recorded.Results The average resting heart rate of patients with hypertension was( 75.1 ±11.7) beats/min,and the usage rate of p-receptor blockers was 11.3%.The achieved rate of resting heart rate controlling( W80 beats/min) was 73.3%,23.6% of patients did not receive β-receptor blockers with resting heart rate > 80 beats/min and 3.0% received p-receptor blockers but resting heart rate was > 80 beats/min.The usage rates of β-receptor blockers between middle, young-aged group and elderly group were not significantly different ( 1 1.7% vs 10.9%, P〉0.05 ), but resting heart rate in elderly group was lower than that in middle and young-aged group [( 73.7±11.3) beats/min vs (76.2 ± 11.9) beiits/min ] and achieved rate of resting heart rate controlling was higher than that in middle and young-aged group(77.9% vs 72.0%) with significant difference (P < 0.05).Conclusion The achieved rate of resting heart rate controlling is low, probably due to the low usage rate of β-receptor blocker.